Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Aug 14, 2018 (8 years ago)

Valsartan Tablets

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

Cause type: Nitrosamine impurity

Trace nitrosamine impurities such as NDMA, NDEA or NMBA found above the acceptable daily limit. Nitrosamines are probable human carcinogens that can form during manufacturing or storage. This is the cause behind the large valsartan, losartan and ranitidine (Zantac) recalls. All nitrosamine impurity recalls.

What was recalled

Valsartan Tablets, USP 40 mg Rx Only NDC 50268-783-15 50 Tablets (5x10) Unit Dose Manufactured for: AvKARE, Inc. Pulaski, TN 38478

Affected NDC 50268-0783-15

Compare with the code on your package — it is the most precise check available.

Drug: Valsartan Category: Blood Pressure Medication

Recalling firm
AVKARE Inc.
NDC code
50268-783-15
Origin
TN, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1130-2018 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Valsartan recalls

See all
Class II · Moderate risk

Diovan (valsartan)

Failed Dissolution Specifications

Ongoing Dissolution failure Novartis Pharmaceuticals Corporation NDC 0078-0359-34 D-0746-2026
Class II · Moderate risk

Valsartan Tablets 320 mg USP

CGMP Deviations; Detection of a trace amount of unexpected impurity N- nitrosodiethylamine (NDEA) found in finished products

Ongoing Nitrosamine impurity Rising Pharmaceuticals, Inc. NDC 52343-125-90 D-1055-2019
Class II · Moderate risk

Valsartan Tablets 160 mg USP

CGMP Deviations; Detection of a trace amount of unexpected impurity N- nitrosodiethylamine (NDEA) found in finished products

Ongoing Nitrosamine impurity Rising Pharmaceuticals, Inc. NDC 52343-124-90 D-1054-2019
Class II · Moderate risk

Valsartan Tablets 80 mg USP

CGMP Deviations; Detection of a trace amount of unexpected impurity N- nitrosodiethylamine (NDEA) found in finished products

Ongoing Nitrosamine impurity Rising Pharmaceuticals, Inc. NDC 52343-123-90 D-1053-2019

Other recalls by AVKARE Inc.

All 2018 recalls
Class II · Moderate risk

Amantadine HCl

Failed Dissolution Specifications: This recall has been initiated due to an Out of Specification finding in dissolution.

Ongoing Dissolution failure AvKARE NDC 50268-069-15 D-0341-2026